Literature DB >> 24760454

[Use of Bone Morphogenetic Proteins (BMPs) for the Treatment of Pseudarthroses - Efficiency and Therapy Failure].

M Hausmann1, S Ehnert1, V Hofmann1, S Döbele1, T Freude1, U Stöckle1, A Nussler1.   

Abstract

In the therapy for pseudarthroses of the proximal tibia, the human recombinant bone morphogenetic proteins (BMP-2 and BMP-7) have been used for several years. Despite their limited and specified use as local mediators of bone healing, no conclusions regarding the therapeutic success can be made beforehand. The regulatory mechanisms have turned out to be much more complex and patient-specific than had been assumed before. To help understand the cell biological processes (signalling) and the current possibilities of predicting a successful use of BMP, this article summarises the relevant findings. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24760454     DOI: 10.1055/s-0034-1368208

Source DB:  PubMed          Journal:  Z Orthop Unfall        ISSN: 1864-6697            Impact factor:   0.923


  3 in total

1.  Comparative study suggests that human bone morphogenetic proteins have no influence on the outcome of operative treatment of aseptic clavicle non-unions.

Authors:  Christian von Rüden; Mario Morgenstern; Jan Friederichs; Peter Augat; Simon Hackl; Alexander Woltmann; Volker Bühren; Christian Hierholzer
Journal:  Int Orthop       Date:  2016-08-13       Impact factor: 3.075

2.  Long-term outcome following additional rhBMP-7 application in revision surgery of aseptic humeral, femoral, and tibial shaft nonunion.

Authors:  Simon Hackl; Christian Hierholzer; Jan Friederichs; Alexander Woltmann; Volker Bühren; Christian von Rüden
Journal:  BMC Musculoskelet Disord       Date:  2017-08-07       Impact factor: 2.362

3.  Pediatric aseptic lower leg fracture nonunion.

Authors:  Christian von Rüden; Sven-Oliver Dietz; Peter Schmittenbecher; Francisco F Fernandez; Justus Lieber; Björn Wilkens; Matthias Rüger; Dorien Schneidmueller
Journal:  Eur J Trauma Emerg Surg       Date:  2020-12-02       Impact factor: 3.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.